Recent Submissions

  • Do current therapeutic anti-A beta antibodies for Alzheimer's disease engage the target? 

    Watt, AD; Crespi, GAN; Down, RA; Ascher, DB; Gunn, A; Perez, KA; McLean, CA; Villemagne, VL; Parker, MW; Barnham, KJ; ... (SPRINGER, 2014-06-01)
    Reducing amyloid-β peptide (Aβ) burden at the pre-symptomatic stages of Alzheimer's disease (AD) is currently the advocated clinical strategy for treating this disease. The most developed method for targeting Aβ is the use ...
  • Peripheral alpha-Defensins 1 and 2 are Elevated in Alzheimer's Disease 

    Watt, AD; Perez, KA; Ang, C-S; O'Donnell, P; Rembach, A; Pertile, KK; Rumble, RL; Trounson, BO; Fowler, CJ; Faux, NG; ... (IOS PRESS, 2015-01-01)
    Biomarkers enabling the preclinical identification of Alzheimer's disease (AD) remain one of the major unmet challenges in the field. The blood cellular fractions offer a viable alternative to current cerebrospinal fluid ...